{"title": "The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study", "doi": "10.1101/2020.03.16.20036145", "citation_id": "2020.03.16.20036145v1", "date": "2020-03-23", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.16.20036145", "abstract": "<p>Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65*109/L vs. 0.76*109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.</p>", "twitter_description": "Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65*109/L vs. 0.76*109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nChiCTR2000030048\n\n### Funding Statement\n\nThis study was funded by Key projects of the Ministry of Science and Technology China \"Preparation of specific plasma and specific globulin from patients with a recovery period of COVID-19 infection\u0094 (project number: 2020YFC0841800).This work was also supported by Shanghai Guangci Translational Medicine Development Foundation.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data associated with the manuscript were available on request", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.16.20036145v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.16.20036145v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.16.20036145v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.16.20036145.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.16.20036145v1", "access_rights": "restricted", "authors": ["Kai Duan", "Bende Liu", "Cesheng Li", "Huajun Zhang", "Ting Yu", "Jieming Qu", "Min Zhou", "Li Chen", "Shengli Meng", "Yong Hu", "Cheng Peng", "Mingchao Yuan", "Jinyan Huang", "Zejun Wang", "Jianhong Yu", "Xiaoxiao Gao", "Dan Wang", "Xiaoqi Yu", "Li Li", "Jiayou Zhang", "Xiao Wu", "Bei Li", "Yanping Yu", "Wei Chen", "Yan Peng", "Yeqin Hu", "Lianzhen Lin", "Xuefei Liu", "Shihe Huang", "Zhijun Zhou", "Lianghao Zhang", "Yue Wang", "Zhi Zhang", "Kun Deng", "Zhiwu Xia", "Qin Gong", "Wei Zhang", "Xiaobei Zheng", "Ying Liu", "Huichuan Yang", "Dongbo Zhou", "Ding Yu", "Jifeng Hou", "Zhengli Shi", "Saijuan Chen", "Zhu Chen", "Xin-xin Zhang", "Xiaoming Yang"]}